Pharmaceutical HOLDRs Trust Pharmaceutical HOLDRs Trust  (PPH) Trade Now »     Rate PPH  -  Discuss PPH  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

PPH: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Healthcare ETFs Outpace the Market PPH

75%

+0.67% in 68 days Healthcare ETFs Outpace the Market The accompanying table presents an analysis and statistics for the 28 healthcare ETFs listed at the Yahoo! Finance ETF Center. As a group, the healthcare ETFs outpaced the overall market in the past year by more than 10%, posting an average loss of 26.5% compared to a loss of 37.4% for the S&P 500 SPDR ETF (SPY). The best performing healthcare ETF was the Biotech HOLDRs (BBH), thanks to a buyout bid for top holding Genetech (DNA) and solid earnings results this year for the number two position, Amgen (AMGN). The top three ... Continue reading »

Generic Drug Industry Outpaces Drug & Healthcare ETFs PPH

75%

+5.81% in 17 days (closed on 11/01/08) Generic Drug Industry Outpaces Drug & Healthcare ETFs The accompanying table presents statistics and the top five rated companies in the ETFI Global Generic Drug Index, which includes a total of 44 companies. Over the past year, generic drug companies have outpaced both the Healthcare Sector SPDR (XLV) and existing drug ETFs such as PowerShares Dynamic Pharma (PJP), Pharma HOLDRs (PPH), iShares Dow Jones US Pharma (IHE), and the S&P Pharma SPDR (XPH). All of the top five rated generic drug companies and over two-thirds of the 44 companies in the index are b ... Continue reading »

Updated FDA Calendar of Decision Dates PPH

75%

-11.73% in 11 days (closed on 10/15/08) Company Name Ticker Date   FDA Decision - Mike Havrilla - Updated 10/3/08 Ligand Pharma LGND 9/19/08 Promacta NDA GlaxoSmithKline GSK 9/19/08 Promacta NDA Abbott Labs ABT 9/21/08 Vicodin CR NDA ... Continue reading »

Eli Lilly Sinks After Hours on Effient Delay PPH

75%

-4.47% in 6 days (closed on 10/04/08) Eli Lilly Sinks After Hours on Effient Delay Eli Lilly (LLY) and Daiichi Sankyo (Tokyo: 4568) announced on Friday evening that the FDA had not completed its regulatory review for its blood thinner drug, which would go by the brand name of Effient (prasugrel). The FDA previously delayed its decision by three months earlier this summer, but in this case no new deadline was set by the agency. Shares of Eli Lilly slid by about 4% after hours on less than 100,000 shares traded, closing near its 52-week low at $45.01 per share on Friday evening. However, the current sli ... Continue reading »

Pfizer is a Big Pharma Buy PPH

75%

+0.70% in 4 days (closed on 09/28/08) Pfizer is a Big Pharma Buy The accompanying table presents an overview of big pharma companies, presented in descending order by market cap. My favorite play in the space remains to be Pfizer (PFE), which I have written about previously and finally bought shares today at $17.90 with a dividend yield exceeding 7%. Despite growth concerns and looming generic competition for Lipitor in late 2011, I bought shares of Pfizer today as a value pick and turnaround play which operates in a defensive sector with a strong balance sheet. Also, the Company is aggressive ... Continue reading »

From the Blogosphere

A New Index of Health Product Innovators

75%

The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices are included in the in... Continue reading »

A New Index of Health Product Innovators

75%

The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices are included in the in... Continue reading »

R&D Leads to Higher Returns for Top 20 Health Innovators

75%

The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices ... Continue reading »

R&D Leads to Higher Returns for Top 20 Health Innovators

75%

The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies which receive original PMA approvals for new medical devices ... Continue reading »

A Bullish Outlook for Generic Drugs After Election

75%

In addition to the favorable underlying trends I wrote about previously for the generic drug industry, both presidential candidates are bullish on the industry with the following excerpts taken directly from their websites: Senator Obama: Lower drug costs by allowing the importation of safe medicines from other developed countries, increasing the use of generic drugs in public programs and taking on drug companies that block cheaper generic medicines from the market. Senator McCain: Reduce drug costs by allowing greater use of generics (including bio-generics). The accompanying table highlight... Continue reading »

Trade PPH Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.